The CAR-T therapy market is projected to grow from $5.76 billion in 2025 to $81.45 billion by 2035 — a compound annual growth rate north of 30%. The science works. Response rates in some blood cancers exceed 60%. Big Pharma is placing billion-dollar bets: Eli Lilly’s $2.4 billion acquisition of Orna Therapeutics, AbbVie’s $2.1 billion move for Capstan Therapeutics, BMS’s $1.5 billion deal for Orbital Therapeutics — all in the last eighteen months, all chasing the next generation of cell and gene therapies.
So why do more than a third of industry leaders say they can’t find the people to run any of it?
A shortage that isn’t new, and isn’t shrinking
This isn’t a post-pandemic blip or a temporary funding hangover. According to BioPlan Associates, which has tracked biopharma workforce data since 2011, hiring difficulty has been a major constraint on manufacturing capacity for more than fifteen years — and the trend line is flat to worse, not improving. In its most recent industry study, BioPlan found that 36% of facilities can’t fill process development roles, 28% can’t hire enough downstream production staff, and 27% lack sufficient process engineers.
Cytiva’s 2025 Global Biopharma Index, surveying 1,250 industry leaders, puts a sharper point on it: more than one in three organizations report severe or critical workforce shortages specifically in emerging modalities like cell and gene therapy. The gaps cluster in a predictable but painful place — process development, GMP manufacturing, quality, and regulatory affairs. In other words: not the scientists who discover the therapy, but the people who know how to take it out of the lab and make it work, reliably, under regulatory scrutiny, at commercial scale.
Why this shortage is structural, not cyclical
Traditional hiring shortages are typically a supply-and-demand timing problem — the market eventually catches up. This one is different, because the industry keeps inventing job categories faster than anyone can train for them.
Five years ago, “in vivo CAR-T” wasn’t a hiring category. Today it’s the fastest-moving front in the field, with Lilly, AbbVie, and a wave of biotechs racing to turn a patient’s own body into the manufacturing site for CAR-T cells — eliminating the need for the extended lab process that autologous therapies require. Every one of these platform shifts — in vivo delivery, allogeneic “off-the-shelf” models, dual-antigen targeting — creates a new specialization with no existing talent pool to draw from. Universities and training pipelines simply cannot turn out GMP-experienced cell therapy leaders on a two-year innovation cycle.
The result, according to a 2026 pharma and biotech hiring analysis from Panda, is a genuinely strange labor market: a “barbell” of simultaneous mass layoffs in some functions and fierce, prolonged competition for specialists in others. Both the layoff narrative and the talent-shortage narrative are true — they’re just describing different parts of the same industry at the same time. Searches for advanced-therapy specialists now routinely take six to nine months, even at strong compensation levels, because the pool of qualified candidates is genuinely small, not just hard to reach.
The part most companies get wrong
When organizations feel this pinch, the instinct is usually to throw more resources at sourcing — more job postings, more recruiters, wider nets. But a wider net doesn’t help when the pool itself is the constraint. Cytiva’s own leadership has pointed to talent gaps, alongside standardization and regulatory pathways, as one of the defining challenges shaping advanced biomanufacturing heading into 2026.
And the shortage isn’t confined to the lab bench. “Bench to Board” is the more accurate framing: the same scarcity that makes it hard to hire a GMP-experienced process engineer also makes it hard to find a Chief Medical Officer who has actually taken a cell therapy through pivotal trials, or a Head of Regulatory Affairs fluent in both AI-driven review pathways and the specific demands of ATMP approval. Some regions are watching this compound — hiring analysts in Australia report that over 80% of biotech respondents expect workforce shortages to negatively affect their strategy over the next five years.
What actually works
The organizations winning in this environment aren’t the ones posting more roles. They’re the ones who’ve accepted that hard-to-reach oncology and cell-therapy talent — whether at the bench or the Board — requires a fundamentally different search approach: deep therapeutic-area fluency, existing relationships with the small population of people who’ve actually done this work before, and the patience to run a proper search rather than a fast one.
The $81 billion opportunity in CAR-T isn’t going to be limited by chemistry. It’s going to be limited by who’s in the room to build it.